Insights for health care providers

• The standard urine culture is used to match known bacterial genomes to identify species of bacteria, most notably E.coli.

• The MyUTI Test identifies the top 12 uropathogens shown to cause recurrent urinary tract infections and symptomatology. Gram-positive and gram-negative bacteria, fungus and resistance genes are detected within a single sample. To support antibiotic stewardship, a comprehensive infectious disease clinical decision support tool provides clinicians with treatment recommendations based on findings.

• Reliable studies show that up to 40% of patients with negative, sub-diagnostic or natural flora results on urine cultures do actually have a pathogenic UTI. Often, these patients are not treated and continue to suffer. The MyUTI Test provides greater detail to support diagnosis and effective treatment, especially in cases where multiple pathogens may be driving a UTI.

• AUA guidelines on recurrent uncomplicated UTIs state that microbial confirmation at the time of acute-onset, urinary-tract-associated symptoms and signs is an important element in establishing a diagnosis of rUTI. The guidelines recommend that clinicians obtain robust diagnostics with each symptomatic acute cystitis episode prior to initiating treatment in patients with rUTIs .

• The MyHome UTI Test is a PCR-based genomic test specially designed to identify 12 uropathogens (bacterial and fungal) that studies show are most frequently involved in UTIs, along with 3 antibiotic resistance genes. This technology is widely trusted and used in many urology specialty practices across the U.S. 

• The MyUTI Test also uses the powerful Arkstone reporting and clinical decision support tool for informed antibiotic selection. Learn more here.

Arkstone technology combines machine-learning artificial intelligence with decades of deep infectious disease expertise to guide physicians to a singular treatment regimen that targets the most relevant infection with the lowest risk to the patient. More information about Arkstone’s OneChoice Report can be found in this video.